Australia's TGA warns against illicit online sales of experimental weight loss drug retatrutide
Updated
Updated · ScienceAlert · Apr 26
Australia's TGA warns against illicit online sales of experimental weight loss drug retatrutide
6 articles · Updated · ScienceAlert · Apr 26
Retatrutide, still in clinical trials and not approved anywhere, is being sold online despite reports of severe side effects, including one death under investigation.
The TGA cautions that unregulated peptide products may be contaminated or incorrectly dosed, posing health risks to both consumers and suppliers.
Retatrutide’s popularity among gym-goers seeking rapid weight loss, dubbed 'leanmaxxing,' is fueled by early trial results, but experts warn of potential psychological and physical risks, including mood changes and muscle loss.
Is the black market for retatrutide driven by reckless vanity or by patients desperate for a cure?
What deadly contaminants are hiding in black-market weight loss drugs shipped from overseas factories?
Is the quest for a 'shredded' physique with new drugs causing a hidden epidemic of muscle loss and frailty?
How will doctors manage patients when a weight loss drug can also alter their personality and relationships?
Why can’t global regulators stop the flood of illegal 'research' peptides being sold openly online?
If new weight loss drugs can make us thin but emotionally 'flat,' are we trading happiness for a perfect body?
TGA Cracks Down on Illicit Peptides: Over 13,700 Illegal Ads Removed as Retatrutide Crisis Escalates
Overview
Australia faces a growing public health crisis as unapproved peptides like retatrutide flood the market, driven by social media hype, easy online access, and shortages of approved weight-loss drugs such as Ozempic. These illicit products are dangerous, often contaminated or mislabeled, causing severe health issues and hospitalizations. Despite promising clinical trial results for retatrutide, it remains unapproved, fueling demand for risky black-market alternatives. In response, the Therapeutic Goods Administration has intensified enforcement, removing thousands of illegal ads and disrupting supply chains. Experts call for combined efforts in public education, healthcare guidance, stricter regulation, and improved access to safe, approved treatments to combat this complex threat.